SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the ...

A Genentech drug to treat a vision loss disorder in an increasing number of diabetics received federal approval Friday despite critics' concerns that the South San Francisco company has promoted the ...

Lucentis (ranibizumab) is a brand-name eye injection that’s prescribed for certain eye conditions in adults. As with other drugs, Lucentis can cause side effects, such as eye pain or irritation. More ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Lucentis is approved for wet age-related macular degeneration (AMD) in over 100 countries. It is also approved for the treatment of visual impairment due to diabetic macular edema (:DME) and macular ...

A landmark study by the National Institutes of Health determines that Lucentis is highly effective as a treatment for diabetic retinopathy. Compared with laser therapy for the treatment of ...

The approval of Cimerli was based on a comprehensive analytical, preclinical and clinical program including the phase 3 COLUMBUS-AMD study. Cimerli, a vascular endothelial growth factor inhibitor, is ...

ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...

Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ...

Medicare, the federal health insurance program for Americans 65 and older, could save $18 billion over the next 10 years if doctors switch to a less expensive drug to treat blindness. The switch could ...